Search
Filter Results
Displaying 1–10 of 41 for “XLRP”
-
May 10, 2021
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
The company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
-
Oct 1, 2019
AGTC Reports Promising Interim Results for XLRP and Achromatopsia Gene Therapy Trials
AGTC used Foundation’s My Retina Tracker registry to recruit patients for trials
-
Feb 9, 2024
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
Feb 7, 2018
AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S.
Taking place at five locations in the United States, the clinical trial will enroll approximately 15 males with X-linked retinitis pigmentosa caused by mutations in the gene RPGR and will primarily evaluate safety.
-
May 17, 2022
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
The three-month results support the planned launch of the company’s Phase 2/3 Vista trial
-
Jan 10, 2020
AGTC Reports Positive Six-Month Results for XLRP Phase 1/2 Gene Therapy Trial
The company is planning a Phase 3, pivotal trial for end of 2020
-
Jul 17, 2020
A Phase 3 trial for the treatment is planned
-
Aug 30, 2017
MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial
The MeiraGTx gene therapy involves injection of healthy copies of RPGR underneath the retina. The RPGR copies are contained in a human-engineered virus — known as an adeno-associated virus or AAV — designed to readily penetrate retinal cells to deliver the therapeutic genetic cargo.
-
May 14, 2021
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
More details from the clinical trial will be reported at a later date
-
Mar 20, 2017
First Patient Treated in XLRP Gene Therapy Clinical Trial
The Nightstar gene therapy involves injection of healthy copies of RPGR underneath the retina.